Y. Ikenaga

CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers

J. Azuma, T. Fukuda, S. Fukuen, 2004, The Pharmacogenomics Journal.

Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population.

J. Azuma, T. Fukuda, S. Fukuen, 2002, Pharmacogenetics.

The frequency of candidate alleles for CYP2D6 genotyping in the Japanese population with an additional respect to the -1584C to G substitution.

J. Azuma, T. Fukuda, Y. Ikenaga, 2005, Drug metabolism and pharmacokinetics.

Effects of the Serotonin Type 2A, 3A and 3B Receptor and the Serotonin Transporter Genes on Paroxetine and Fluvoxamine Efficacy and Adverse Drug Reactions in Depressed Japanese Patients

T. Kinoshita, G. Okugawa, J. Azuma, 2006, Neuropsychobiology.

ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder

A. Serretti, L. Mandelli, T. Kinoshita, 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.

S. Kiuchi, Yoshinobu Nakamaru, K. Ueta, 2015, Journal of pharmacological sciences.

Novel structure of the CYP2D6 gene that confuses genotyping for the CYP2D6*5 allele.

J. Azuma, T. Fukuda, Y. Ikenaga, 2005, Drug Metabolism and Pharmacokinetics.

The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.

S. Kiuchi, Yoshinobu Nakamaru, K. Ueta, 2015, Journal of pharmacological sciences.

Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism

T. Kinoshita, G. Okugawa, J. Azuma, 2005, International clinical psychopharmacology.